Gui-Long Guo

618 total citations
24 papers, 479 citations indexed

About

Gui-Long Guo is a scholar working on Oncology, Cancer Research and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Gui-Long Guo has authored 24 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Gui-Long Guo's work include Breast Cancer Treatment Studies (5 papers), Thyroid Cancer Diagnosis and Treatment (5 papers) and Estrogen and related hormone effects (4 papers). Gui-Long Guo is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Thyroid Cancer Diagnosis and Treatment (5 papers) and Estrogen and related hormone effects (4 papers). Gui-Long Guo collaborates with scholars based in China, Belgium and Italy. Gui-Long Guo's co-authors include Ouchen Wang, Xiaohua Zhang, Jie You, Wei Zhang, Yili Zhou, Yinlong Yang, Ming‐Hua Zheng, Youqun Xiang, Tingting Ye and Han Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Oncology and Medicine.

In The Last Decade

Gui-Long Guo

22 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gui-Long Guo China	13	200	169	161	98	91	24	479
Miaw‐Jene Liou Taiwan	16	393 2.0×	196 1.2×	112 0.7×	62 0.6×	109 1.2×	35	597
Hyunju Park South Korea	16	277 1.4×	179 1.1×	129 0.8×	51 0.5×	157 1.7×	52	648
Young Bum Yoo South Korea	10	209 1.0×	107 0.6×	114 0.7×	48 0.5×	87 1.0×	30	473
Jiwang Liang China	14	131 0.7×	305 1.8×	122 0.8×	108 1.1×	155 1.7×	24	658
Kazuma Maeno Japan	10	108 0.5×	82 0.5×	214 1.3×	55 0.6×	144 1.6×	32	444
Chi‐Jen Chang Taiwan	15	106 0.5×	159 0.9×	43 0.3×	91 0.9×	138 1.5×	42	574
Elisabetta Cavedon Italy	18	527 2.6×	150 0.9×	129 0.8×	187 1.9×	274 3.0×	25	791
Hsin‐An Chen Taiwan	8	108 0.5×	142 0.8×	45 0.3×	82 0.8×	110 1.2×	21	366
Luigi Sandonato Italy	10	148 0.7×	217 1.3×	56 0.3×	45 0.5×	43 0.5×	27	530

Countries citing papers authored by Gui-Long Guo

Since Specialization

Citations

This map shows the geographic impact of Gui-Long Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gui-Long Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gui-Long Guo more than expected).

Fields of papers citing papers by Gui-Long Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gui-Long Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gui-Long Guo. The network helps show where Gui-Long Guo may publish in the future.

Co-authorship network of co-authors of Gui-Long Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Gui-Long Guo. A scholar is included among the top collaborators of Gui-Long Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gui-Long Guo. Gui-Long Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gu, Haitao, et al.. (2025). A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer. Cancer Management and Research. Volume 17. 441–460.

Zhu, Teng, et al.. (2025). Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer. Breast Cancer Targets and Therapy. Volume 17. 201–210.

Yang, Xiaohong, Hui Zhou, Zhihong Liu, et al.. (2023). P-145 Efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a real-world setting. Annals of Oncology. 34. S66–S66. 1 indexed citations

Guo, Gui-Long, et al.. (2022). Male Breast Carcinoma Metastatic to the Choroid: A Case Report and Opinions of Management. SHILAP Revista de lepidopterología. 2 indexed citations

Shi, Hao, et al.. (2021). Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer. Future Oncology. 17(36). 5077–5091. 2 indexed citations

Shi, Hao, et al.. (2019). <p>Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients</p>. Cancer Management and Research. Volume 11. 10827–10839. 22 indexed citations

Dai, Xuanxuan, Changtian Yin, Yi Zhang, et al.. (2018). Osthole inhibits triple negative breast cancer cells by suppressing STAT3. Journal of Experimental & Clinical Cancer Research. 37(1). 322–322. 68 indexed citations

You, Jie, Huxiang Zhang, Yanyan Shen, et al.. (2017). Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients. OncoTargets and Therapy. Volume 10. 2199–2208. 18 indexed citations

Ma, Ruimin, et al.. (2016). Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer. Medicine. 95(13). e3240–e3240. 19 indexed citations

10.

Ma, Ruimin, et al.. (2016). [Lack of progesterone receptor expression predicts poor prognosis in patients with operable ER-positive invasive breast cancer].. PubMed. 38(9). 687–92. 1 indexed citations

11.

You, Jie, Sha Huang, Guiqian Huang, et al.. (2015). Nonalcoholic Fatty Liver Disease. Medicine. 94(5). e479–e479. 22 indexed citations

12.

Xiang, Youqun, Yinlong Yang, Gui-Long Guo, et al.. (2015). β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer. Clinical and Experimental Medicine. 16(3). 391–397. 4 indexed citations

13.

Cai, Yefeng, Qingxuan Wang, Gui-Long Guo, et al.. (2015). The Clinical Relevance of Psammoma Body and Hashimoto Thyroiditis in Papillary Thyroid Carcinoma. Medicine. 94(44). e1881–e1881. 14 indexed citations

14.

Yang, Yinlong, Zimiao Chen, Yizuo Chen, et al.. (2014). Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clinical Endocrinology. 81(2). 282–288. 82 indexed citations

15.

Zhou, Yili, Wei Zhang, Han Yang, et al.. (2012). Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: a retrospective study. World Journal of Surgical Oncology. 10(1). 67–67. 66 indexed citations

16.

Huang, Ou, Weili Wu, Ouchen Wang, et al.. (2011). Sentinel lymph node biopsy is unsuitable for routine practice in younger female patients with unilateral low-risk papillary thyroid carcinoma. BMC Cancer. 11(1). 386–386. 24 indexed citations

17.

Guo, Gui-Long, et al.. (2008). [The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer].. PubMed. 46(2). 132–5. 5 indexed citations

18.

Guo, Gui-Long, et al.. (2007). Isolation of side population cells and detection of ABCG2 from SW480. Chinese Journal of Cancer Research. 19(4). 238–243. 1 indexed citations

19.

Guo, Gui-Long, et al.. (2005). [The effect of selective cyclooxygenase-2 inhibitor nimesulide on breast cancer induced by dimethylbenzoic acid in rats].. PubMed. 43(15). 1017–20. 1 indexed citations

20.

Guo, Gui-Long, et al.. (2003). [The clinical significance of expression of cyclooxygenase-2 gene in breast cancer].. PubMed. 83(19). 1661–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact